Psoriatic Arthritis |Clinical Guidance

Clinical Action Points

Expand all

Recognize the genetic and pathophysiological factors contributing to psoriatic arthritis (PsA) to understand its complex etiology.
Identify the various clinical presentations of PsA, including asymmetrical oligoarthritis, symmetrical polyarthritis, and axial arthritis.
Utilize the CASPAR criteria for accurate diagnosis of PsA, ensuring early and precise identification.
Consider TNF inhibitors like etanercept and infliximab for patients with moderate to severe PsA.
Explore other biologic therapies, including IL-17 inhibitors and IL-23 inhibitors, for refractory PsA cases.
Review coordinated management strategies for patients with both PsA and psoriasis to optimize overall care.
Monitor treatment efficacy and safety, follow guidelines, adjusting therapeutic approaches as necessary to manage PsA effectively.